Erudio Healtherudio.com
Drug
Volrustomig trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying volrustomig: eVOLVE-Lung02. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| eVOLVE-Lung02 NCT05984277 · AstraZeneca | first-line metastatic non-small cell lung cancer | Phase 3 | 37 | 10 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NeoCOAST-2 NCT05061550 · AstraZeneca DeepView → | resectable stage II–IIIB non-small cell lung cancer | Phase 2 | Deep | View | |||
| DESTINY-Gastric03 NCT04379596 · AstraZeneca DeepView → | advanced HER2-expressing gastric cancer | Phase 2 | Deep | View | |||
| DESTINY-Lung03 NCT04686305 · AstraZeneca DeepView → | first-line advanced or metastatic HER2-overexpressing non-squamous NSCLC | Phase 1 | Deep | View | |||
| TROPION-PanTumor03 NCT05489211 · AstraZeneca FocusedView → | advanced/metastatic solid tumors | Phase 2 | Focused | View | |||